CID 9913172

BeschreibungLipobay was launched in Denmark, Germany and the UK for treatment of primary hypercholesteremia types Ⅱa and Ⅱb. It is available through a nine step synthesis beginning with the Hantsch reaction of ethyl 3-amino-4-methylpent-2-enoate and 4-(ethoxycarbonyl)-5-(4-fluorophenyl)-2-methylpent-4-en-3-one. Lipobay acts as an HMG-CoA reductase inhibitor showing a high liver selectivity (50 fold). In vitro Lipobay had a higher affinity (110x) for the enzyme than does Lovastatin, Simvastatin and pravastatin which resulted in a lower ED50, in vivo compared to Lovastatin. Three metabolites generated by the CYP3A4 enzyme system were equal to the parent in activity. Lipobay was as effective as Gemfibrozil in type lib hypercholesteremia and had no age or gender effects. It decreased plasma levels of VLDL and LDL cholesterol by a mechanism similar to other HMG-CoA reductase inhibitors. The (-)- antipode is completely inactive indicating a high stereospecificity by the enzyme. It is therapeutically useful at ultra-low doses which may minimize any drug-drug interactions.

VerwendenCerivastatin sodium salt hydrate has been used as a supplement in cell culture.